QTORIN 3.9% rapamycin anhydrous gel
PALV-10
Phase 2 small_molecule active
Quick answer
QTORIN 3.9% rapamycin anhydrous gel for Cutaneous Venous Malformations is a Phase 2 program (small_molecule) at PALVELLA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PALVELLA THERAPEUTICS, INC.
- Indication
- Cutaneous Venous Malformations
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active